| Latest Palatin Tech News Headlines | | Date | Time | Source | | | 12/09/2008 | 7:30AM | PRNUS | Palatin Technologies Announces Extension of Research Collaboration and License Agreement with AstraZeneca
Enters into Clinical Trial Sponsored Research Agreement
CRANBURY, N.J., Dec. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) today announced an extension of its exclusive research collaboration and license agreement with AstraZeneca (NYSE:AZN) to discover, develop and commercialize compounds that target... More...>> |
| 11/17/2008 | 7:30AM | PRNUS | Palatin Technologies, Inc. Reports Fiscal Year 2009 First Quarter Results; Teleconference and Webcast To Be Held on November 17,
CRANBURY, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today results for its first quarter ended September 30, 2008. Palatin reported a net loss of $4.3 million, or $(0.05) per basic and diluted share, for the quarter ended September 30, 2008, compared to a net loss of $247,000... More...>> |
| 11/13/2008 | 10:06AM | PRNUS | Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
CRANBURY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the open of the U.S. financial markets.
The Company will also conduct a conference call and live audio webcast hosted by Palatin's... More...>> |
| 09/30/2008 | 11:36AM | PRNUS | Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2008 and provide an update on corporate developments during a conference call and webcast on September 30, 2008 at 11:15 a.m. ET... More...>> |
| 09/30/2008 | 7:30AM | PRNUS | Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on Sep
CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today results for its fourth quarter and fiscal year ended June 30, 2008. Palatin reported a net loss of $5.2 million, or $(0.06) per basic and diluted share, for the quarter ended June 30, 2008, compared to a net loss... More...>> |
| 09/25/2008 | 7:30AM | PRNUS | Palatin Technologies to Report Fourth Quarter and Fiscal Year End 2008 Financial Results; Conference Call and Webcast on Septemb
CRANBURY, N.J., Sept. 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will announce its fourth quarter and fiscal year end 2008 financial results on September 30, 2008 before the open of the U.S. financial markets.
The Company will also conduct a conference call and live audio webcast hosted by Palatin's... More...>> |
| 09/23/2008 | 8:47AM | PRNUS | Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Associat
CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of heart failure, at the 12th... More...>> |
| 08/14/2008 | 7:30AM | PRNUS | Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
CRANBURY, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF). The Phase 2a trial was a randomized... More...>> |
| 07/01/2008 | 7:30AM | PRNUS | Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
CRANBURY, N.J., July 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) today announced that AstraZeneca and Palatin have amended their exclusive global licensing and research collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors. The original agreement... More...>> |
| 05/20/2008 | 7:30AM | PRNUS | Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
CRANBURY, N.J., May 20 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today that dosing has been initiated in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.
The study is placebo-controlled and double-blinded... More...>> |
| 05/13/2008 | 7:30AM | PRNUS | Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) today reported its financial results for the third quarter ended March 31, 2008 and announced new strategic objectives as part of a restructuring of its clinical-stage product portfolio and development programs. Palatin will continue... More...>> |
| 05/08/2008 | 7:30AM | PRNUS | Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
CRANBURY, N.J., May 8 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will announce its third quarter, fiscal year 2008 financial results for the period ended March 31, 2008 before the open of the U.S. financial markets on May 13, 2008.
The Company will also conduct a teleconference and live audio webcast... More...>> |
| 03/10/2008 | 8:30AM | PRNUS | Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Hea
CRANBURY, N.J., March 10 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today the completion of a Phase I clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of acute decompensated congestive heart failure (CHF). The... More...>> |
| 02/11/2008 | 7:30AM | PRNUS | Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11
CRANBURY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today financial results for the second quarter ended December 31, 2007. Palatin reported a net loss of $3.8 million, or ($0.04) per basic and diluted share, for the quarter ended December 31, 2007, compared to a net loss... More...>> |
| 02/05/2008 | 5:00PM | PRNUS | Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will announce its second quarter, fiscal year 2008 financial results for the period ended December 31, 2007 on February 11, 2008 before the open of the U.S. financial markets.
The Company will also conduct a teleconference and live... More...>> |
| 01/22/2008 | 8:05AM | PRNUS | Palatin Technologies Announces Litigation Settlement With Competitive Technologies
CRANBURY, N.J., Jan. 22 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today that it entered into an agreement to settle all outstanding litigation and disputes with Competitive Technologies, Inc. (AMEX:CTT) related to a license agreement between the companies. Under the terms of the settlement... More...>> |
| 11/09/2007 | 7:30AM | PRNUS | Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9,
CRANBURY, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today financial results for the first quarter ended September 30, 2007. Palatin reported a net loss of $247,000, or $0.00 per basic and diluted share, for the quarter ended September 30, 2007, compared to a net loss of... More...>> |
| 11/05/2007 | 4:05PM | PRNUS | Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
CRANBURY, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) will announce its first quarter, fiscal year 2008 financial results on November 9, 2007 before the open of the U.S. financial markets.
The Company will also conduct a teleconference and live audio webcast hosted by Palatin's executive... More...>> |
| 11/02/2007 | 4:00PM | PRNUS | Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
CRANBURY, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) today announced that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at the New York Palace Hotel in New York on Monday, November 5, 2007 at 4:45 PM ET.
Carl Spana, Ph.D., President and Chief... More...>> |
| 10/31/2007 | 8:22AM | PRNUS | Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
CRANBURY, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX:PTN) announced today the initiation of dosing in a Phase 1 clinical trial of PL-3994, a long acting analog of atrial natriuretic peptide, under development for treatment of acute decompensated congestive heart failure (CHF). The trial... More...>> |
|